Intrahepatic cholangiocarcinoma: Primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival

Annals of Surgery

Volumn 252, Issue 1, 2010, Pages 107-114

  Ercolani, Giorgio ^a   Vetrone, Gaetano ^a   Grazi, Gian Luca ^a   Aramaki, Osamu ^a   Cescon, Matteo ^a   Ravaioli, Matteo ^a   Serra, Carla ^a   Brandi, Giovanni ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOOD TRANSFUSION; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 77954083028     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181e462e6     Document Type: Article

References (61)

1. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol. 1999;14: 1144-1149.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholan-giocarcinoma in the United States. Hepatology. 2001;33:1353-1357.
3. Shaib Y, El-Sareg HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-125.
4. Shaib Y, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40:472-477.
5. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816-820.
6. Wood R, Brewster DH, Fraser LA, et al. Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer. 2003;39:2087-2092.
7. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221-1228.
8. Liver Cancer Study Group of Japan. Classification of Primary Liver Cancer. 1st English ed. Tokyo, Japan: Kanehara; 1997.
9. Cherqui D, Tantawi B, Alon R, et al. Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg. 1995;130:1073-1078.
10. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84-96.
11. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755-762.
12. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangio-carcinoma: operative results and long-term outcome. Surgery. 2008;143:366-374.
13. Jonas S, Thelen A, Benckert C, et al. Extended liver resection for intrahepatic cholangiocarcinoma. A comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg. 2009;249:303-309.
14. Uenishi T, Hirohashi K, Kubo S, et al. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg. 2001;88:969-974.
15. Madariaga JR, Iwatsuki S, Todo S, et al. Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases. Ann Surg. 1998;227:70-79.
16. Uenishi T, Hirohashi K, Kubo S, et al. Histological factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg. 2001;25:865-869.
17. Ohtsuka M, Ito H, Kimura F, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89:1525-1531.
18. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51(suppl 6):VI1-VI9.
19. Tajima Y, Kuroki T, Fukuda K, et al. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg. 2004;91:99-104.
20. Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005;35: 68-73.
21. Vogl TJ, Schwarz W, Eichler K, et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 2006;132:745-755.
22. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96:896-902.
23. Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J. 2006;12:113-122.
24. Slakey DP. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg. 2002;68:395-397.
25. Zgodzinski W, Espat NJ. Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11: 5239-5240.
26. Tepel J, Hinz S, Klomp HJ, et al. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. Eur J Surg Oncol. 2004;30:551-555.
27. Chiou YY, Hwang JI, Chou YH, et al. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci. 2005;21:304-309.
28. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16:353-361.
29. Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Inter-vent Radiol. 2007;30:1156-1165.
30. Gusani NJ, Balaa FK, Steel JL, et al. Treatment of unresectable cholangio-carcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single institution experience. J Gastrointest Surg. 2008;12:129-137.
31. Suzuki S, Sakaguchi T, Yokoi Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocar-cinoma. World J Surg. 2002;26:687-693.
32. Sotiropoulos GC, Lang H, Broelsch CE. Surgical management of recurrent intrahepatic cholangiocellular carcinoma after liver resection. Surgery. 2005; 137:669-670.
33. Grazi GL, Ercolani G, Pierangeli F, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71-78.
34. Cescon M, Vetrone G, Grazi GL, et al. Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg. 2009;249:995-1002.
35. Strasberg S, Belghiti J, Clavien PA, et al. The Brisbane 2000 terminology of liver anatomy and resection. HPB Surg. 2000;2:333-339.
36. Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:6289-6297.
37. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg. 2000;87:1182-1187.
38. Inoue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127:498-505.
39. Yamamoto Y, Takasaki K, Otsudo T, et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001;8: 154-157.
40. Jan Y, Yeh CN, Yeh TS, et al. Clinicopathological factors predicting long term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg. 2005;29:894-898.
41. Paik KY, Jung JC, Heo JS, et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol. 2008;23: 766-770.
42. Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobili-ary Pancreat Surg. 2008;15:417-422.
43. Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:2787-2794.
44. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology. 2000;214: 761-768.
45. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-827.
46. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1997;185:429-436.
47. Lee GW, Kang JH, Kim HG, et al. Combination chemotherapy with gemcit-abine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol. 2006;29:127-131.
48. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317-323.
49. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48:783-789.
50. André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
51. Knox JJ, Hedley D, Oza A, et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004;15:770-774.
52. Knox JJ, Hedley D, Oza D, et al. Combination gemcitabine and capecitabine in patients with advanced biliary cancer: a phase 2 trial. J Clin Oncol. 2005;23:2332-2338.
53. de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is still a contraindication to surgery? Ann Surg. 2008;248:626-637.
54. Ercolani G, Grazi GL, Ravaioli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg. 2004;239:202-209.
55. Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: respectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193: 384-391.
56. Shirabe K, Shimada M, Harimoto N, et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery. 2002;131(suppl 1):S159-S164.
57. Asakura H, Ohtsuka M, Ito H, et al. Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology. 2005;52:722.
58. Puhalla H, Schuell B, Pokorny H, et al. Treatment and outcome of intrahe-patic cholangiocellular carcinoma. Am J Surg. 2005;189:173-177.
59. Tamandl D, Kaczirek K, Gruenberger B, et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg. 2009;96: 919-925.
60. Corvera CU, Blumgart LH, Akhurst T, et al. FDG-PET influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206: 57-65.
61. D'Angelica M, Fong Y, Weber S, et al. The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol. 2003;10:183-189.